TPhreo jeocbt jescutmivme aoryf : Project 1 is to understand the biochemical and cellular mechanisms for terminating endocannabinoid (EC) signaling in the nervous system. The two major ECs, anandamide (AEA) and 2- arachidonoylglycerol (2-AG), are degraded by disfinct enzymatic pathways in vivo. AEA is principally regulated by the integral membrane enzyme fatty acid amide hydrolase (FAAH), which also hydrolyzes several other bioactive fatty acid amides, including the anti-infiammatory lipid A/-palmitoyl ethanolamine, the satiating factor A/-oleoyl ethanolamine, and the TRP channel agonist A/-arachidonoyl taurine. A major challenge in understanding FAAH-regulated fatty acid amide signaling is to discriminate the distinct physiological functions of endogenous FAAH substrates. 2-AG is hydrolyzed by several enzymes in the brain, including the soluble enzyme monoacylglycerol lipase (MAGL) and the integral membrane hydrolases ABHD6 and ABHD12. A major challenge in understanding 2-AG signaling is to determine the unique biochemical and cellular properties of individual 2-AG hydrolytic enzymes. Prior to enzymatic hydrolysis, both AEA and 2-AG may interact with binding proteins responsible for cellular uptake and transport. A major challenge in understanding EC uptake and transport is to identify the putative proteins that mediate these processes. In the previous funding period, we used a combination of synthetic chemistry, enzymology, molecular biology, and functional proteomic/metabolomic methods to enrich our understanding of EC degradative pathways. We have also developed powerful new chemical and genetic tools to probe the function of these pathways. In this renewal application, we plan to use our suite of chemical and genetic tools to gain further mechanistic insights into EC degradative pathways. Specifically, we aim to: 1) characterize mouse models with altered EC degradative pathways, 2) characterize the biochemical and cell biological properties of brain 2-AG hydrolases, and 3) map lipid-protein interactions in EC degradative pathways using chemical proteomic methods. We anticipate that these studies will enhance our understanding of the biochemical pathways that terminate EC signaling in the nervous system and define key components in these pathways that may serve as drug targets for the treatment of a range of human disorders, including pain, depression, and metabolic disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Program Projects (P01)
Project #
5P01DA017259-10
Application #
8484801
Study Section
Human Development Research Subcommittee (NIDA)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
10
Fiscal Year
2013
Total Cost
$489,045
Indirect Cost
$135,368
Name
Scripps Research Institute
Department
Type
DUNS #
781613492
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Wills, Kiri L; Petrie, Gavin N; Millett, Geneva et al. (2016) Double Dissociation of Monoacylglycerol Lipase Inhibition and CB1 Antagonism in the Central Amygdala, Basolateral Amygdala, and the Interoceptive Insular Cortex on the Affective Properties of Acute Naloxone-Precipitated Morphine Withdrawal in Rats. Neuropsychopharmacology 41:1865-73
Wilkerson, J L; Ghosh, S; Bagdas, D et al. (2016) Diacylglycerol lipase β inhibition reverses nociceptive behaviour in mouse models of inflammatory and neuropathic pain. Br J Pharmacol 173:1678-92
Wilkerson, Jenny L; Niphakis, Micah J; Grim, Travis W et al. (2016) The Selective Monoacylglycerol Lipase Inhibitor MJN110 Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model. J Pharmacol Exp Ther 357:145-56
Gamage, Thomas F; Ignatowska-Jankowska, Bogna M; Muldoon, Pretal P et al. (2015) Differential effects of endocannabinoid catabolic inhibitors on morphine withdrawal in mice. Drug Alcohol Depend 146:7-16
Dincheva, Iva; Drysdale, Andrew T; Hartley, Catherine A et al. (2015) FAAH genetic variation enhances fronto-amygdala function in mouse and human. Nat Commun 6:6395
Ghosh, Sudeshna; Kinsey, Steven G; Liu, Qing-Song et al. (2015) Full Fatty Acid Amide Hydrolase Inhibition Combined with Partial Monoacylglycerol Lipase Inhibition: Augmented and Sustained Antinociceptive Effects with Reduced Cannabimimetic Side Effects in Mice. J Pharmacol Exp Ther 354:111-20
Muldoon, P P; Chen, J; Harenza, J L et al. (2015) Inhibition of monoacylglycerol lipase reduces nicotine withdrawal. Br J Pharmacol 172:869-82
Nass, Sara R; Long, Jonathan Z; Schlosburg, Joel E et al. (2015) Endocannabinoid Catabolic Enzymes Play Differential Roles in Thermal Homeostasis in Response to Environmental or Immune Challenge. J Neuroimmune Pharmacol 10:364-70
Wiebelhaus, Jason M; Grim, Travis W; Owens, Robert A et al. (2015) Δ9-tetrahydrocannabinol and endocannabinoid degradative enzyme inhibitors attenuate intracranial self-stimulation in mice. J Pharmacol Exp Ther 352:195-207
Gamage, Thomas F; Ignatowska-Jankowska, Bogna M; Wiley, Jenny L et al. (2014) In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569. Behav Pharmacol 25:182-5

Showing the most recent 10 out of 134 publications